# Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

> **NCT00425204** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 31 (actual)

## Conditions studied

- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Prostate Cancer
- Solid Tumors
- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Panitumumab (ABX-EGF)

## Key facts

- **NCT ID:** NCT00425204
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-09
- **Final completion:** 2008-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2008-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425204, "Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00425204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*